2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
10
INDUSTRY
2
FED
1
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
3210
Carcinoma, Non-Small-Cell Lung
2721
Breast Neoplasms
2547
Colorectal Neoplasms
1454
Prostatic Neoplasms
1303
Neoplasm Metastasis
1292
Multiple Myeloma
1109
Melanoma
1101
Ovarian Neoplasms
1001
Lung Neoplasms
941
Recurrence
921
Leukemia, Myeloid, Acute
876
Pancreatic Neoplasms
830
Lymphoma, Non-Hodgkin
766
Lymphoma
713
Stomach Neoplasms
691
Carcinoma, Renal Cell
658
Carcinoma, Hepatocellular
645
Leukemia, Lymphocytic, Chronic, B-Cell
560
Squamous Cell Carcinoma of Head and Neck
546
Lymphoma, Follicular
515
Head and Neck Neoplasms
488
Glioblastoma
472
Small Cell Lung Carcinoma
444
Lymphoma, Large B-Cell, Diffuse
440
Triple Negative Breast Neoplasms
433
Advanced Solid Tumors
430
Leukemia
426
Uterine Cervical Neoplasms
418
Urinary Bladder Neoplasms
405
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphatic Abnormalities
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT06239480
2026-03-27
SELVA
Palvella Therapeutics, Inc.
Phase 3
Active not recruiting
51 enrolled